Literature DB >> 9952062

Memory deficits associated with recreational use of "ecstasy" (MDMA).

M J Morgan1.   

Abstract

Evidence from both animal, and human, studies suggests that repeated administration of 3,4-methylenedioxymethamphetamine (MDMA: "ecstasy") produces lasting decreases in serotonergic activity. Serotonin is believed to play a modulatory role in a variety of psychological processes, including learning and memory. There are recent reports that polydrug users, who have used ecstasy recreationally, exhibit selective impairments in memory. However, these studies did not compare ecstasy users with polydrug users who had not taken ecstasy, leaving open the possibility that the memory deficits may be associated with a history of use of other illicit drugs. The present study used the Rivermead Behavioural Memory test to investigate immediate and delayed recall in: 25 polydrug-users who had taken more than 20 tablets of ecstasy (MDMA group), 22 participants (polydrug controls) who had never taken ecstasy, but, otherwise has personal characteristics (e.g. age, gender, education, height, weight), and illicit drug use histories, that were generally not significantly different from those of the MDMA group, and 19 participants who had not used illicit drugs but who also had similar personal characteristics (non-drug controls). Participants in the MDMA group recalled significantly fewer ideas (approximately 75% of the number of ideas recalled by participants in either of the other two groups), in both immediate and delayed recall conditions. The two illicit drug-using groups did differ in their estimated IQ scores and their duration of use of LSD, but only the latter proved to be a statistically significant covariate, and the difference in recall performance between the MDMA and polydrug controls groups remained statistically significant when this variable was treated as a covariate. The present findings provide the first evidence that deficits in memory performance in recreational ecstasy users are primarily associated with past exposure to ecstasy, rather than with the other legal and illicit drugs consumed by these individuals, and are consistent with reduced serotonergic modulation of mnemonic function as a result of long-term neurotoxic effects of MDMA in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952062     DOI: 10.1007/s002130050803

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

Review 1.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

2.  (±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.

Authors:  Ann M Hemmerle; Jonathan W Dickerson; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams; Kim B Seroogy
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

3.  Risky car following in abstinent users of MDMA.

Authors:  Elizabeth Dastrup; Monica N Lees; Antoine Bechara; Jeffrey D Dawson; Matthew Rizzo
Journal:  Accid Anal Prev       Date:  2010-05

4.  Reasoning deficits in ecstasy (MDMA) polydrug users.

Authors:  John E Fisk; Catharine Montgomery; Michelle Wareing; Philip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

5.  The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe; Phillip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.

Authors:  Jonathan P Roiser; Robert D Rogers; Lynnette J Cook; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-08-29       Impact factor: 4.530

7.  Chronic cognitive impairment in users of 'ecstasy' and cannabis.

Authors:  Anthony Klugman; John Gruzelier
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 8.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

9.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

10.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.